Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that allow us to develop a deep understanding of the links between a compound’s chemical structure, biological function and its manufacturing process. We are applying our innovative technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
In 2010, we validated our approach to the development of highly complex molecules by becoming the first company to achieve U.S. regulatory approval of a generic version of LOVENOX® (enoxaparin sodium injection) for the treatment of deep vein thrombosis (DVT). In 2015, we received U.S. regulatory approval for and launched our second complex generic, Glatopa™ (glatiramer acetate injection), a fully substitutable generic version of daily COPAXONE® 20 mg. Glatopa is the only approved generic drug available to date for the treatment of patients with relapsing-forms of multiple sclerosis.
Today, Momenta’s development pipeline extends beyond complex generics to include biosimilars and novel drug candidates. We have made a substantial investment in analytics and characterization technology and, for our pipeline of drug candidates, in understanding the relationship between their structural composition and the manufacturing process parameters. Momenta’s goal is to continue pushing our science forward to develop products that create value for patients, our healthcare system and our shareholders.
LOVENOX® is a registered trademark of Sanofi-Aventis. COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd. Glatopa™ is a registered trademark of Novartis AG. Enoxaparin Sodium Injection and Glatopa™ were developed under a collaboration agreement between Momenta and Sandoz. Both products are marketed under the Sandoz brand.
Last Updated 9/6/2016